Stock Events

Stock Events

Alaunos Therapeutics 

$1.8800
32
-$0.03-1.57% Tuesday 20:00
-$0.01-0.57%Tuesday 22:05After hours

Statistics

Day High
1.9
Day Low
1.83
52W High
4.59
52W Low
1.67
Volume
7,776
Avg. Volume
15,262
Mkt Cap
4.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
Next
-6.44
-5.52
-4.6
-3.69
Expected EPS
N/A
Actual EPS
N/A

Financials

-83,520%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5,000Revenue
-4.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCRT. It's not an investment recommendation.
Apple
8
AAPL
Microsoft
8
MSFT
Tesla
8
TSLA
Amazon
8
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. has a strong presence in cell therapy for cancer, competing in the same space as Alaunos with its Yescarta and other cellular therapies.
Novartis
NVS
Mkt Cap286.78B
Novartis AG has been a pioneer in CAR-T cell therapy for cancer, competing in the broader market of advanced cancer therapies alongside Alaunos.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. has investments in cancer therapy, including CAR-T and potentially TCR-like therapies, making it a competitor in the oncology space.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is heavily involved in cancer treatment through immunotherapy and could potentially expand into TCR therapies, competing with Alaunos.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb Company has a broad portfolio in oncology, including cell therapies, which could compete with Alaunos's TCR approaches.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its Janssen subsidiary, is investing in cancer therapies, including cell therapy, posing potential competition to Alaunos.

About

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Show more...
CEO
Holger Weis
Employees
1
Country
United States
ISIN
US98973P3091

Listings

MU
DE
WEK.MU
XNAS
US
TCRT
BOATS
BOATS
TCRT.BOATS

0 Comments

Share your thoughts

FAQ

What is Alaunos Therapeutics stock price today?▼
The current price of TCRT is $1.88 USD — it has decreased by -1.57% in the past 24 hours. Watch Alaunos Therapeutics stock price performance more closely on the chart.
What is Alaunos Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Alaunos Therapeutics stocks are traded under the ticker TCRT.
Is Alaunos Therapeutics stock price growing?▼
TCRT stock has fallen by -6% compared to the previous week, the month change is a -8.29% fall, over the last year Alaunos Therapeutics has showed a -16.07% decrease.
What is Alaunos Therapeutics market cap?▼
Today Alaunos Therapeutics has the market capitalization of 4.59M
When is the next Alaunos Therapeutics earnings date?▼
Alaunos Therapeutics is going to release the next earnings report on November 17, 2026.
What is Alaunos Therapeutics revenue for the last year?▼
Alaunos Therapeutics revenue for the last year amounts to 5,000 USD.
What is Alaunos Therapeutics net income for the last year?▼
TCRT net income for the last year is -4.18M USD.
How many employees does Alaunos Therapeutics have?▼
As of August 19, 2026, the company has 1 employees.
In which sector is Alaunos Therapeutics located?▼
Alaunos Therapeutics operates in the Health & Wellness sector.
When did Alaunos Therapeutics complete a stock split?▼
The last stock split for Alaunos Therapeutics was on July 18, 2024 with a ratio of 1:10.
Where is Alaunos Therapeutics headquartered?▼
Alaunos Therapeutics is headquartered in FORT LAUDERDALE, United States.